Abstract
BACKGROUND CONTEXT Chemotherapy has dramatically improved survival in many primary bone tumors. Bone tumors of the vertebral column (BTVCs) are rarer and the impact of chemotherapy on these tumors is not well established. We investigated the largest registry of primary bone tumors, the National Cancer Database (NCDB). PURPOSE Our goal was to determine the impact of chemotherapy on outcomes in patients with primary BTVCs. STUDY DESIGN/SETTING Retrospective National Cancer Database review. PATIENT SAMPLE All patients identified in the National Cancer Database with primary bone tumors of the vertebral column. These were further stratified based on the use or nonuse of chemotherapy. OUTCOME MEASURES Patient survival was the primary outcome measure. METHODS We retrospectively analyzed patients in the NCDB from 2004 through 2015. Patients were stratified based on chemotherapy use for primary BTVCs; these were further stratified by histologic subtype. Univariate and multivariate analyzes were used to correlate specific outcome measures with these factors. Then, long-term survival between groups was evaluated using the Kaplan-Meier (KM) method with statistical comparisons based on the log-rank test. Multiple variables were analyzed between the two groups. RESULTS We identified 941 patients presenting with primary BTVCs. Thirty-seven patients were treated with chemotherapy alone, 293 were treated with surgery alone, and 72 were treated with both surgery and chemotherapy; 78/127 patients with osteosarcoma (61.4%) and 146/164 patients with Ewing's Sarcoma (89%) underwent chemotherapy as compared to 16/243 patients with chondrosarcoma (6.6%) and 14/407 patients with chordoma (3.4%). Across the entire cohort of patients, patients who received chemotherapy were on average, younger (38 vs. 56 years, p CONCLUSIONS This is the largest patient cohort to date examining the impact of chemotherapy on primary BTVCs. Chemotherapy use was far more likely for Ewing's sarcoma and osteosarcoma than chordoma and chondrosarcoma. Patients with either osteosarcoma or Ewing's sarcoma receiving surgery in addition to chemo had improved overall survival than those undergoing surgery alone. Further investigation is necessary to help improve the appropriate delivery of adjuvant therapies to patients with primary BVTCs. FDA DEVICE/DRUG STATUS This abstract does not discuss or include any applicable devices or drugs.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
